ASH 2022 | Ocular AEs observed in patients treated with belantamab mafodotin, lenalidomide & dexamethasone
Evangelos Terpos, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, highlights the ocular adverse events (AEs) observed in the Phase I/II BelaRd study (NCT04808037), which is investigating the safety and clinical activity of belantamab mafodotin in combination with lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma (MM). Worsening of cataracts was observed, but no grade 3 or 4 events were recorded. Prof. Terpos also mentions that a questionnaire indicated that most patients experienced a very low frequency of ocular events which affected their daily activity. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
GSK: Honoraria, Research Funding; BMS: Honoraria; EUSA Pharma: Honoraria, Other: Travel expenses; Amgen: Honoraria, Other: Travel expenses, Research Funding; Sanofi: Honoraria, Research Funding; Takeda: Honoraria, Other: Travel expenses, Research Funding; Genesis: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Novartis: Honoraria.
